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Abstract
Epigenetic silencing of tumor suppressor genes is a new focus of investigation in the generation and proliferation
of carcinomas. Secreted protein acidic and rich in cysteine (SPARC) is reportedly detrimental to the growth of
ovarian cancer cells and has been shown to be epigenetically silenced in several cancers. We hypothesized that
SPARC is downregulated in ovarian cancer through aberrant promoter hypermethylation. To that end, we analyzed
SPARC expression in ovarian cancer cell lines and investigated the methylation status of the Sparc promoter using
methylation-specific polymerase chain reaction. Our results show that SPARC mRNA expression is decreased in
three (33%) and absent in four (44%) of the nine ovarian cancer cell lines studied, which correlated with hyper-
methylation of the Sparc promoter. Treatment with the demethylating agent 5-aza-2′-deoxycytidine rescued SPARC
mRNA and protein expression. Addition of exogenous SPARC, as well as ectopic expression by an adenoviral vec-
tor, resulted in decreased proliferation of ovarian cancer cell lines. Investigation of primary tumors revealed that the
Sparc promoter is methylated in 68% of primary ovarian tumors and that the levels of SPARC protein decrease as
the disease progresses from low to high grade. Lastly, de novo methylation of Sparc promoter was shown to be
mediated by DNA methyltransferase 3a. These results implicate Sparc promoter methylation as an important factor
in the genesis and survival of ovarian carcinomas and provide new insights into the potential use of SPARC as a
novel biomarker and/or treatment modality for this disease.
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Introduction
With more than 21,000 new cases and more than 15,000 deaths ex-
pected in 2008, ovarian cancer ranks as the fifth leading cause of
cancer deaths in women (http://www.cancer.org). More than 90%
of ovarian cancers in humans arise from the surface epithelial cells
of the ovaries. Recent studies have shown that several tumor suppres-
sor genes are methylated in ovarian cancer [1–8]. Epigenetic silencing
of tumor suppressor genes by methylation is rapidly becoming an
area of interest in cancer research. Methylation most often occurs
at cytosines that are 5′ to guanosine (known as the CpG dinucleo-
tide) [9]. Stretches of DNA that are rich in CpG dinucleotides are
known as CpG islands and can be found proximal to the promoter
region of approximately 50% of human genes [9]. Methylation of
these normally protected CpG islands results in the silencing of the
alleles downstream of the promoter regions [10].
The secreted protein acidic and rich in cysteine (SPARC), also known
as osteonectin, BM-40, and 43K protein, is a membrane-associated
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glycoprotein that belongs to the matricellular family of proteins [11].
SPARC is predominantly expressed in tissues undergoing remodeling
or repair, and it also plays an important role in normal development
[12]. In addition to its antiproliferative and de-adhesive properties,
SPARC is known to play a role in angiogenesis and extracellular
matrix production [13]. The role of SPARC in tumor development
and metastasis varies owing to the contextuality of its functions
[14]. SPARC is significantly downregulated in ovarian cancer cells,
and restoring its expression leads to decreased tumor growth and
apoptosis [15]. Our laboratory has previously shown that SPARC
ameliorates peritoneal carcinomatosis by inhibiting tumor cell adhe-
sion and invasion during metastasis [16]. We have also identified
roles for SPARC in ovarian cancer integrin–mediated adhesion and
lysophosphatidic acid–induced mesothelial–ovarian cancer cell cross talk
[17,18]. Therefore, SPARC plays a pivotal role in controlling malignancy
of ovarian carcinoma.
In this study, we have attempted to elucidate the mechanism by
which ovarian carcinoma cells downregulate SPARC expression. We
hypothesized that epigenetic silencing of Sparc by aberrant methylation
during ovarian carcinogenesis is responsible for the down-regulation of
SPARC. To that end, we examined the in vitro methylation status of
the Sparc promoter in ovarian cancer cell lines, immortalized control
cell lines, and nonimmortalized, normal human ovarian surface epithe-
lial (NHOSE) primary cells. The in vivo correlate studies were per-
formed in tumor tissue samples from patients with serous ovarian
cancer in varying stages and grades. Our results revealed that the
down-regulation of SPARC in ovarian cancer cells is indeed caused
by the hypermethylation of the Sparc promoter and that the loss of
SPARC protein expression is inversely correlated with tumor grade.
Moreover, demethylation of the CpG islands by 5-aza-2′-deoxycytidine
(5-Aza-CdR) resulted in the restored expression of SPARC, and chro-
matin immunoprecipitation (ChIP) studies revealed DNA methyl-
transferase 3a (DNMT3a) as the major DNMT responsible for
de novo methylation of Sparc promoter in ovarian cancer cells.
Materials and Methods
Cell Culture and Tumor Tissue Samples
We studied nine human ovarian cancer cell lines: SKOV3, TOV112,
OVCAR3, OVCA 420, OVCA 429, DOV 13, OV-90, TOV21, and
PA-1. OVCA 420, OVCA 429, and DOV 13 were prepared as pre-
viously described [6]. The remaining cell lines were purchased from
American Type Culture Collection (ATCC, Manassas, VA). SKOV3
was grown in McCoy’s 5A medium (Sigma-Aldrich, St. Louis, MO)
supplemented with 15% fetal bovine serum (FBS; Atlanta Biologicals,
Norcross, GA) as well as penicillin, streptomycin, and amphotericin B
(PSA; Sigma). OVCAR3 was grown in RPMI 1640 (ATCC), 15%
FBS, PSA, and 50 μg/ml bovine insulin (Sigma). PA-1 was grown
in Dulbecco’s modified Eagle’s medium (Sigma), 10% FBS, PSA.
OVCA 420, OVCA 429, and DOV 13 were all grown in a mixture
of MCDB105 (Sigma) and M199 (Sigma) media (1:1), 10% FBS,
PSA. TOV112, OV-90, and TOV21 were all grown in MCDB105/
M199 media (1:1), 15% FBS, PSA. Control cell lines Meso 301 (an
immortalized mesothelial cell line), HOSE 1-15 (an immortalized
human ovarian surface epithelial cell line), and three nonimmortalized,
NHOSE primary cultures (preparations 56, 58, and 59) were obtained
as previously described [6,19] and grown in MCDB105/M199 media
(1:1), 10% FBS, PSA. All cell lines were incubated in 5% CO2 at
37°C. Highly undifferentiated (grade III) serous-type ovarian carci-
noma tumor samples from patients with varying disease stages (FIGO
stages I-IV) were obtained from an in-house tumor tissue bank (De-
partment of Pathology, Medical College of Georgia) with an approved
institutional review board protocol. Samples were embedded in paraf-
fin blocks and sectioned for microdissection. Ovarian cancer tumor
cells were selectively microdissected from sections at our in-house laser
capture microdissection (LCM) core facility and were stored at 4°C
for later analysis.
Reagents and Antibodies
SPARC from mouse parietal yolk sac was purchased from Sigma.
Human and bovine osteonectin were purchased from Haematologic
Technologies Inc. (Essex, VT). Anti-human SPARC antibodies were
purchased from Haematologic Technologies Inc. and Santa Cruz Bio-
technology (Santa Cruz, CA). Anti-DNMT antibodies were obtained
from Epigentek (Brooklyn, NY). 5-Aza-CdR and trichostatin A (TSA)
were purchased from Sigma-Aldrich and MP Biomedicals (Irvine,
CA), respectively.
Reverse Transcription–Polymerase Chain Reaction
Reverse transcription–polymerase chain reaction (RT-PCR) was
used to assess the levels of SPARC mRNA expression in the cell lines.
Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad,
CA) according to manufacturer’s protocol and further purified with
the RNeasy isolation kit (Qiagen, Valencia, CA). Two micrograms of
RNA was reverse-transcribed using oligo-(dT) primer and Improm-II
Reverse Transcriptase (Promega, Madison, WI) into cDNA for sub-
sequent PCR analysis. Polymerase chain reaction amplification was
performed using JumpStart TAQ (Sigma) with the following general
protocol: initial denaturation at 95°C for 4 minutes, followed by a
variable number of cycles of 95°C for 30 seconds, specific annealing
temperature for 45 seconds, 72°C for 1 minute, and a final elongation
at 72°C for 8 minutes. Primer sequences, annealing temperatures, and
cycle numbers can be found in Table 1. PCR products were visualized
on 2% agarose gels containing ethidium bromide and photographed
using a Kodak Gel Logic 100 imaging system and Kodak 1-D 3.6 soft-
ware (Eastman Kodak, Rochester, NY).
Real-time Quantitative PCR
The real-time quantitative PCR (qPCR) analyses were performed
with primers designed from human Sparc promoter sequences
(GenBank Accession No. U65081) using a Bio-Rad iQ5 cycler
(Hercules, CA). Sense primer (32-52): 5′-GGA TCA TGA GGT
CAG GCA TT-3′. Antisense primer (210-230): 5′-GCT GGA GTG
CAG TGG TAT GA-3′. The qPCR reaction cocktail, PerfeCTa SYBR
Green SuperMix for iQ, was purchased from Quanta BioSciences
(Gaithersburg, MD). The qPCR was performed in 25-μl reaction vol-
umes with an initial cycle at 95°C for 3 minutes, followed by 40 cycles
at 95°C for 10 seconds, and at 60°C for 30 seconds. Because equal
amounts of the same input were used in all samples, the ratio between
positive ChIP and negative ChIP (Positive IP/Negative IP) was used
to determine the ChIP efficiency. Relative occupancy of the immuno-
precipitated factor at Sparc locus was calculated using the following
equation: Relative occupancy = 2[C t (Negative control) − C t(Target)], where
C t (Negative control) and C t (Target) are mean threshold cycles of
PCR done in triplicates on DNA samples from negative control ChIP
Neoplasia Vol. 11, No. 2, 2009 Aberrant Methylation of Sparc in Ovarian Cancer Socha et al. 127
(using nonimmune IgG) and targeted ChIP (using specific DNMT
isoform-specific antibodies), respectively.
Immunoblot Analysis
Protein lysates were prepared for Western blot analysis from cul-
tured cells. The cells were washed with cold Dulbecco’s phosphate-
buffered saline (PBS; Sigma), lysed in RIPA buffer containing sodium
orthovanadate and a cocktail of protease inhibitors, and sonicated
as previously described [16]. Protein concentrations were determined
using the BCA Protein Assay Kit (Pierce, Rockford, IL). Lysates were
mixed with 1× SDS sample buffer, boiled for 5 minutes, and ana-
lyzed by SDS-PAGE. Proteins were then transferred to Immun-Blot
PVDF Membrane (Bio-Rad) and blocked with 5% BSA in PBS.
The membranes were washed with PBS containing 0.2% Tween
20 (PBS-T) and incubated with anti-human SPARC overnight. After
washing with PBS-T, the membranes were incubated with horseradish
peroxidase–conjugated donkey anti-mouse IgG (Jackson Immuno-
Research Laboratories Inc., West Grove, PA) for 1 hour. Signals were
visualized using the SuperSignal West Dura Extended Duration Sub-
strate (Pierce). Photography and densitometry measurements were
performed using a Kodak Gel Logic 100 imaging system and Kodak
1-D 3.6 software (Eastman Kodak).
Methylation-Specific PCR
Genomic DNA was isolated from cell lines and LCM tumor cells
from tissue sections using DNAzol Reagent (Invitrogen) according to
the protocol recommended by the manufacturer. Methylation pat-
terns were analyzed using methylation-specific PCR (MSP) adopted
from Herman et al. [20]. Genomic DNA (1 μg, or 500 ng when
sample was not large enough) was treated with sodium bisulfite using
the EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA)
according to the protocol recommended by the manufacturer. Two
microliters of the final eluant was used for subsequent PCR amplifi-
cation. The primer sequences as well as annealing temperatures and
cycle numbers were derived from a published study and can be found
in Table 1 [21]. Polymerase chain reaction products were visualized
on 2% agarose gels containing ethidium bromide and were photo-
graphed using a Kodak Gel Logic 100 imaging system and Kodak
1-D 3.6 software (Eastman Kodak).
5-Aza-CdR and TSA Treatments
Nine ovarian cancer cell lines (SKOV3, TOV112, OVCAR3,
OVCA 420, OVCA 429, DOV 13, OV-90, TOV21, and PA-1) at
65% confluence were treated with the global genomic DNA de-
methylating agent 5-Aza-CdR or the histone deacetylase inhibitor
TSA. For the 5-Aza-CdR treatment, cells were seeded in six-well cul-
ture dishes and incubated overnight in growth media. The normal
growth media were replaced with growth media supplemented with
5-Aza-CdR (6 μM final concentration) and was replenished daily for
5 days. For the TSA treatment, cells were seeded in 60-mm culture
dishes and incubated in their respective growth media containing
TSA (500 ng/ml) for 24 hours. At the conclusion of either treatment,
cells were harvested for RNA, genomic DNA, and protein as de-
scribed above.
Immunohistochemistry
SPARC levels in ovarian cancer tissue was analyzed by immuno-
histochemistry using ovarian cancer tissue arrays OV801 and OV2001
(US Biomax, Rockville, MD) containing 133 serous papillary adeno-
carcinoma samples of varying TNM stages and grades (T1 Nx Mx,
n = 118; T2 Nx Mx, n = 13; T3 Nx Mx, n = 2; grade I, n = 17;
grade II, n = 38; grade III, n = 78). For immunostaining, slides were
deparaffinized and rehydrated before being incubated in 0.3% H2O2
in methanol to block endogenous peroxidases. Slides were then treated
with AutoZyme (BioMeda Corp, Foster City, CA) before incubating
with anti-human SPARC overnight. After washing with PBS-T, the
slides were incubated with a horseradish peroxidase–conjugated sec-
ondary antibody for 1 hour before being developed with Vectastain
ABC Elite Kit (Vector Laboratories, Burlingame, CA) and stable
3,3′-diaminobenzidine (ResGen, Huntsville, AL). Slides were then
counterstained with hematoxylin and mounted. Images were acquired
with a Leica microscope (DM5000) equipped with a Q-Imaging digi-
tal camera (Leica Microsystems, Wetzlar, Germany). To quantify the
SPARC staining, images of each section were assigned random num-
bers and scored by three observers blinded to the study on a scale of 0
to 4 for SPARC protein in the tumor and stroma.
Cell Proliferation Assays and Doubling Time Measurements
Bromodeoxyuridine proliferation assay. Proliferation was mea-
sured using bromodeoxyuridine (BrdU) incorporation as a marker
of DNA synthesis. The Cell Proliferation Biotrak ELISA System
(Amersham Biosciences, Piscataway, NJ) was used according to the
manufacturer’s protocol. A total of 2500 cells in 100 μl of growth
media were seeded in a 96-well plate in triplicate. After being allowed
to adhere overnight, the media were switched to the respective ex-
perimental conditions (with or without exogenous SPARC), and
the cells were incubated for 48 hours. After 48 hours, the cells were
labeled with 100 μM BrdU for 3 hours at 37°C and 5% CO2 in a
humidified incubator. Cells were then fixed, incubated in blocking
buffer, and treated with anti-BrdU antibody for 90 minutes. The cells
Table 1. Polymerase Chain Reaction Primer Sequences, Annealing Temperatures, and Cycle Numbers Used in RT-PCR and MSP Experiments.
Gene Forward Primer Reverse Primer Annealing Temperature (°C) Cycle Number
RT-PCR primers
SPARC 5′-AAGATCCATGAGAATGACAAG-3′ 5′-AAAAGCGGGTGGTGCAATG-3′ 65 30
DNMT1 5′-GGGACGACGGGAAGACCTACT-3′ 5′-CTCGCTGGAGTGGACTTGTG-3′ 60 40
DNMT3a 5′-ACGACGACGACGGCTACCAGT-3′ 5′-TTGCGAGCAGGGTTGACGAT-3′ 61 40
DNMT3b 5′-AAAGCCCAGCTGTCCGAACTC-3′ 5′-GAACTTGCCATCGCCAAACC-3′ 59 40
GAPDH 5′-CACTGGCGTCTT CACCACCATG-3′ 5′-GCTTCACCACCTTCTTGATGTCA-3′ 56 30
MSP primers
Methylated Sparc 5′-GAGAGCGCGTTTTGTTTGTC-3′ 5′-AACGACGTAAACGAAAATATCG-3′ 62 40
Unmethylated SPARC 5′-TTTTTTAGATTG TTTGGAGAGTG-3′ 5′-AACTAACAACATAAACAAAAATATC-3′ 52 40
128 Aberrant Methylation of Sparc in Ovarian Cancer Socha et al. Neoplasia Vol. 11, No. 2, 2009
were washed extensively with the provided wash buffer, developed with
tetramethylbenzidine substrate for 20 minutes and stopped with 1 M
sulfuric acid, and the absorbance was read at 450 nm.
Calculation of doubling time. Ovarian cancer cell lines were trans-
duced with an adenovirus-overexpressing SPARC to assess the effect
of SPARC expression on doubling times. Generation of replication-
deficient adenoviruses expressing either green fluorescent protein
(GFP) or SPARC-GFP constructs under the control of the cytomegalo-
virus promoter was reported previously [18]. After viral infection,
the ovarian cancer cells were seeded in 24-well plates for 96 hours in three
groups: wild type (WT) untransduced cells, cells transduced with GFP
construct (GFP), and cells transduced with SPARC-GFP construct
(SPARC-GFP). Cells from each group were trypsinized and counted
to determine the doubling time. The experiments were performed in
quadruplicates, and the results are expressed as the mean ± SEM.
Nonradioactive cell proliferation assay. Cell proliferation was
measure using a CellTiter96 kit (Promega) as previously described [18].
Previously, adenovirus-infected cells (described above) were seeded in
96-well plates and allowed to adhere overnight in growth media. The
next day, the number of proliferating cells was determined colorim-
etrically by measuring the absorbance at 590 nm of the dissolved
formazan product after the addition of (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H -tetrazolium) (MTS)
for 3 hours, as recommended by the manufacturer. The experiments
were performed in triplicates, and the results are expressed as the
mean ± SEM.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation studies were performed with Im-
print ChIP kit (Sigma). SKOV3 cells (1 × 107) were cross-linked
with 1% formaldehyde (Pierce), and the cell nuclei were isolated, in-
cubated with cell lysis buffer, and sonicated with 15 × 5-second
pulses. Equal amounts of sonicated chromatin were immunoprecipi-
tated with 1 μg of each of the following antibodies: mouse IgG, RNA
polymerase II (provided in the ChIP kit), DNMT1, DNMT3a, and
DNMT3b (Epigentek). The chromatin was washed, and the cross-
links were hydrolyzed. The DNA was then purified through DNA
binding column and subjected to qPCR analysis. The PCR primers
were derived from a 1.3-kb region upstream of Sparc translation start
site, the sequences of which contain CpG islands.
Statistical Analysis
Scoring of the arrays was analyzed for statistical significance using
a one-way analysis of variance followed by a Bonferroni correction.
Doubling times and proliferation data are presented as mean ± SEM.
To determine statistical differences between groups in the prolifera-
tion assays and ChIP assays, statistical differences were determined by
2-tailed t tests. A P value of <.05 was considered statistically signifi-
cant for all data.
Results
Decreased Expression of SPARC in Ovarian Cancer Is Caused
by Aberrant Methylation
SPARC expression was examined by RT-PCR in nine ovarian can-
cer cell lines, two immortalized control lines, and three nonimmor-
talized HOSE primary cultures. Sparc mRNA expression was present
in HOSE 1-15 and Meso 301 (data not shown) cell lines as well as in
all three of the NHOSE samples (Figure 1A). However, expression
was decreased in three (33%) and absent in four (44%) of the nine
ovarian cancer cell lines investigated. Only DOV 13 and PA-1
showed Sparc mRNA levels comparable to those of the positive con-
trols. Western blot analysis of the cell lines confirmed that SPARC
protein was present in HOSE 1-15 and Meso 301 cell lines, as well as
in all three of the NHOSE samples (Figure 1B). Conversely, SPARC
protein was absent in the lysates from seven (77%) of the ovarian
cancer cell lines. Only DOV 13 and PA-1 exhibited SPARC protein
expression, albeit at a significantly reduced level compared to positive
controls. This discrepancy can be attributed, at least in part, to dif-
ferences in posttranscriptional regulation of SPARC (e.g., differences
in the rates of translation, RNA/protein stability, and/or expression
of microRNAs) in normal versus malignant cells. Investigation by
MSP revealed that in the cell lines lacking expression of SPARC,
the Sparc gene was methylated (Figure 1C ). Conversely, DNA from
normal samples, including Meso 301, HOSE 1-15, and three
NHOSE samples, showed no methylation of the Sparc gene.
Rescue of SPARC Expression by 5-Aza-CdR Treatment
To confirm that methylation of the Sparc gene is responsible for
the loss of SPARC protein expression, the ovarian cancer cells lines
that were positive for Sparc methylation were treated with the de-
methylating agent 5-Aza-CdR. The 5-Aza-CdR treatment was able
to restore SPARC mRNA expression in the cell lines that did not
originally express SPARC (SKOV3, TOV112, OVCAR3) but had
no significant effect on HOSE 1-15 or Meso 301 (Figure 2A). More-
over, protein expression was restored in five (71.4%) of the seven cell
lines previously lacking SPARC expression (Figure 2B). OV-90 and
TOV21 showed no significant increase in SPARC protein expression.
Conversely, PA-1 responded well to 5-Aza-CdR treatment regardless
of its relatively high basal levels of SPARC protein, suggesting that
this cell line has hemimethylation of the Sparc promoter (one allele
methylated, one unmethylated). We also investigated whether his-
tone acetylation played a role in the regulation of Sparc transcription.
Treatment of the ovarian cancer cell lines with the histone deacetylase
inhibitor TSA did not significantly enhance Sparc mRNA expression,
except for OV-90 (Figure 2C ). These results suggest that other epi-
genetic mechanisms, bedsides methylation, may account for the
regulation of SPARC in a minor subpopulation of epithelial ovarian
carcinoma cell lines.
Sparc Is Aberrantly Methylated in Primary Ovarian Tumors
In an effort to show that the methylation of Sparc is not an artifact
found only in cultured cells, we obtained 22 high-grade, primary
serous ovarian tumor samples for analysis. The samples were micro-
dissected by LCM to ensure minimal stromal cell contamination of
the tumor samples. Methylation-specific PCR of the tumors showed
that of the 22, 15 (68.2%) had full methylation of the SPARC pro-
moter, 5 (22.7%) showed hemimethylation, and only 2 (9.1%) showed
no methylation. A representative MSP analysis of these tumors is shown
in Figure 3A. In addition to looking at the methylation status of Sparc,
we obtained two ovarian cancer tumor arrays containing a total of 133
samples of serous ovarian carcinoma at varying disease stages (TNM
stages 1-3) and grades (I-III) to investigate the levels of SPARC protein
in primary tumors by immunohistochemistry (T1 NxMx, n = 118; T2
Nx Mx, n = 13; T3 Nx Mx, n = 2; grade I, n = 17; grade II, n = 38;
grade III, n = 78). The results showed that significantly lower levels of
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SPARC protein are present in the tumors compared to the surrounding
normal stroma, suggesting that the tumor production of SPARC is di-
minished (Figure 3B). In addition, our results indicate that there is a
clear decrease in the levels of SPARC protein in both the tumor and the
surrounding stromal cells as the tumor becomes more undifferentiated
(higher grade).
Ectopic Overexpression or Exogenous Addition of SPARC
Inhibits Proliferation of Ovarian Cancer Cells
To determine the significance behind the methylation of Sparc in
ovarian cancer, we investigated the effects of both addition of exoge-
nous SPARC and restoring SPARC expression on the ovarian cancer
cell lines lacking SPARC (Figure W1). Measurement of proliferation
rates by BrdU incorporation after the addition of exogenous SPARC
protein to culture media of ovarian cancer cells showed a significant
decrease in proliferation (Figure 4A). Proliferation rates decreased by
39.9% for SKOV3, 26.6% for TOV112, 37.2% for OVCAR3, and
14.1% for OVCA 420. In addition, inducing the ovarian cancer cells
to express SPARC through the use of an adenovirus resulted in both
an increase in their doubling time (SKOV3, 103.6%; TOV112,
215.7%; OVCAR3, 55.4%; OVCA 420, 156.0%; DOV 13,
128.9%; TOV21, 55.0%; Figure 4B) and a decrease in their rate of
proliferation as measured by an MTS assay (SKOV3, 26.0%;
TOV112, 32.1%; OVCAR3, 25.3%; OVCA 420, 37.5%; DOV 13,
38.3%; TOV21, 24.8%; Figure 4C).
Association of DNMT3a with Sparc Promoter in SKOV3 Cells
In an effort to determine if the aberrant methylation of Sparc pro-
moter was the result of changes in DNMT expression, we examined
the expression of the DMNT isoforms DNMT (1, 3a, and 3b)
through RT-PCR. DNMT1 is a maintenance methyltransferase, re-
sponsible for adding methyl groups to hemimethylated DNA during
replication, whereas DNMT3a and DNMT3b are de novo methyl-
transferases, adding methyl groups to CpG islands that are initially
unmethylated [22]. Whereas DNMT1 and DNMT3b showed no
significant differences in mRNA expression levels (data not shown),
DNMT3a expression levels were found to be elevated in the nine
ovarian cancer cell lines, relative to the normal HOSE controls (Fig-
ure 5A). Comparison of basal levels of DNMT protein levels in
SKOV3 and OVCAR3 ovarian cancer cell lines revealed abundant
levels of DNMT3a, low levels of DNMT1, and undetectable levels of
DNMT3b (Figure 5, B and C). It has been reported that 5-Aza-CdR is
a potent inhibitor of DNMT1 and DNMT3a but not DNMT3b in
colon cancer cells [23]. Our results showed that 5-Aza-CdR treatment
significantly suppressed protein levels of DNMT3a in both SKOV3
and OVCAR3, whereas levels of DNMT1 were only significantly re-
duced in SKOV3 cells. As expected, expression of SPARC was increased
in both cell lines.
To determine the mechanism by which the methylation of Sparc
promoter is regulated, we used a ChIP assay to identify which
DNMT associates with Sparc promoter in SKOV3 cells. Our results
showed that DNMT3a antibody precipitated Sparc promoter DNA
detected by qPCR (approximately four-fold over IgG control), sug-
gesting that Sparc promoter in SKOV3 is associated with DNMT3a
but not DNMT1 or DNMT3b (Figure 5D). As a positive control,
RNA polymerase II was shown to be associated with Sparc promoter
(14-fold over IgG control). Furthermore, 5-Aza-CdR treatment resulted
in a significant (∼1.5-fold) decrease in the association of DNMT3a with
Figure 1. SPARC expression is reduced in ovarian cancer cell lines caused by aberrant methylation. (A) Expression levels of SPARC mea-
sured by RT-PCR in nine ovarian cancer cell lines, one immortalized control cell line (HOSE 1-15), and three primary cell lines (NHOSE 56,
58, and 59). Pictures shown are representative of three independent experiments. (B) Expression of SPARC protein from nine ovarian
cancer cell lines, two immortalized control cell lines (HOSE 1-15 and Meso 301), and three primary cell lines measured by Western blot.
Blots shown are representative of three independent experiments. (C) Representative examples of MSP of the Sparc promoter in three
ovarian cancer cell lines and two immortalized control cell lines. Results shown are representative of three independent experiments.
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Figure 2. Restoration of SparcmRNA and protein expression through global demethylation is independent of histone acetylation in vitro.
(A) Expression of SparcmRNA measured by RT-PCR from three representative ovarian cancer cell lines and two normal control cell lines
before (right) and after (left) treatment with 5-Aza-CdR. Pictures shown are representative of three independent experiments. (B) Expres-
sion levels of SPARC protein measured by Western blot analysis in nine ovarian cancer cell lines and two normal control cell lines before
(top) and after treatment (bottom) with 5-Aza-CdR. Blots shown are representative of three independent experiments. (C) Expression of
SPARC mRNA as measured by RT-PCR from six representative ovarian cancer cell lines before (left) and after (right) treatment with TSA,
a histone deacetylase inhibitor. These results confirm that, with the exception of DOV 13 cell line, histone acetylation seems to play no
significant role in SPARC expression. Results shown are representative of three independent experiments.
Figure 3. Sparc is aberrantly methylated in ovarian cancer tumor tissue, and this methylation results in an inverse correlation between
disease stage and SPARC levels. (A) Methylation-specific PCR analysis of the Sparc promoter from laser-captured ovarian tumor samples.
Images are representative of methylation, hemimethylation, and no methylation of the promoter. Pictures shown are representative of
three independent experiments. (B) Graphical representation of the relative levels of SPARC protein present in tumor samples of varying
grades. Images were blindly scored on a scale of 0 to 4 for SPARC staining intensity (*P< .05 vs stroma; #P< .05 vs grade I stroma; +P< .05
vs grade II stroma; ψp < .05 vs grade I tumor).
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the Sparc promoter (Figure 5E). Taken together, these results suggest
that DNMT3a is mostly responsible for the aberrant de novo methyla-
tion of Sparc promoter, resulting in down-regulation of SPARC expres-
sion in ovarian cancer cell lines.
Discussion
In this study, we sought to determine the mechanism through
which SPARC expression is diminished in human ovarian carcinoma.
Our results indicate that hypermethylation of the promoter sequence
is the primary mechanism through which SPARC is downregulated.
Previous groups have demonstrated that in multiple neoplasms, includ-
ing pancreatic, lung, colon, and endometrial carcinomas, the down-
regulation of SPARC expression was the result of epigenetic silencing
through methylation of the Sparc promoter [21,24–26]. In con-
cordance with these studies, we observed that the loss of SPARC ex-
pression in ovarian carcinoma correlated with increased methylation
and that this loss of expression could be rescued in ovarian cancer
cell lines on treatment with the demethylating agent 5-Aza-CdR.
These findings indicate that although methylation may not be the only
mechanism down-regulating SPARC, it is the primary mechanism in
ovarian cancer.
It has been hypothesized that CpG island hypermethylation is
simply a means to enable gene silencing through reorganization of
chromatin into a silenced state through histone deacetylation [27].
This is supported by the evidence that inhibition of histone deacety-
lase restored the expression of methylated genes [28]. It has also been
suggested that methylation and histone deacetylation act in syn-
ergy, as multiple layers of epigenetic gene silencing [29]. Our results
using 5-Aza-CdR and TSA indicate that inhibition of DNA methyla-
tion, but not histone deacetylation, was sufficient to restore expres-
sion of SPARC in most of the cell lines investigated. However, only
OV-90 cell line showed a significant increase in Sparc mRNA after
TSA treatment but did not restore SPARC protein expression after
5-Aza-CdR treatment. These data suggest that in the OV-90 cell line,
SPARC is most likely downregulated through histone deacetylation
Figure 4. Exogenous SPARC inhibits proliferation of ovarian cancer in vitro. (A) BrdU incorporation in the absence or presence of ex-
ogenous SPARC (40 μg/ml) shows that in the four ovarian cancer cell lines, SPARC inhibits proliferation. Results shown are expressed as
the mean ± SEM and were representative of two independent experiments performed in quadruplicates (*P < .05). (B) Measurements
of the doubling time of six of the ovarian cancer cell lines showed significant increases after induction of SPARC production through an
adenoviral vector (*P < .05). (C) MTS assay on the six ovarian cancer cell lines expressing SPARC after adenoviral infection shows a
significant decrease in the proliferation rate of the cells. Results shown are expressed as the mean ± SEM and were representative of
two independent experiments performed in triplicates (*P < .05).
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but not promoter hypermethylation. However, the preponderance of
evidence suggests that hypermethylation of the promoter region is the
primary mechanism responsible for SPARC down-regulation.
In our present study, we investigated whether changes in DNMT
expression were responsible for the aberrant methylation of the Sparc
promoter. No differences were observed in the mRNA or protein ex-
pression levels of DNMT1 and DNMT3b mRNA, but a significant
increase in that of DNMT3a in most of the ovarian cancer cell lines,
compared to the immortalized HOSE controls. There is controversy
regarding correlations between DNMT overexpression, CpG island
hypermethylation, and neoplasm malignancy. Whereas some studies
have shown a direct correlation between up-regulation of DNMTs
and the development of neoplasms [30,31], others have reported
no such associations [32,33]. Down-regulation of SPARC in ovarian
carcinoma seems to enhance growth and metastasis of the neoplasm.
We have previously shown that SPARC acts as a negative regulator of
ovarian cancer metastasis in mice [16]. This suggests that the expres-
sion of SPARC could act to impair ovarian carcinoma growth. A pre-
vious study also concluded that SPARC is upregulated in reactive
stroma, particularly at the tumor-stromal interface of the invading
tumors [34]. Moreover, it is in accordance with our findings that
both exogenous SPARC and ectopic SPARC expression inhibit the
proliferation of ovarian cancer cells. Interestingly, a recent report re-
vealed that transfer of normal human chromosome 3p fragments into
ovarian cancer cells suppressed their tumorigenicity, which was cor-
related with the up-regulation of SPARC [35]. These studies, along
with the results presented herein, persuasively implicate SPARC as a
tumor suppressor in ovarian carcinoma.
The results of the ovarian cancer tumor tissue array indicated an
inverse correlation between SPARC protein expression and tumor
Figure 5. DNMT3a associates with Sparc promoter in ovarian cancer cells. (A) Expression of DNMT3a mRNA measured by RT-PCR in nine
ovarian cancer cell lines and one immortalized control cell line show that this DNMT isoform is upregulated in ovarian cancer cells. The
human breast cancer cell line MCF7, overexpressing the DNMT3a isoform, was used as a positive control. Pictures shown are represen-
tative of three independent experiments. (B) Basal and 5-Aza-CdR–treated protein levels of SPARC and DNMT isoforms in SKOV3 and
OVCAR3 cell lines. 5-Aza-CdR treatment resulted in a significant increase in SPARC expression, but only significantly reduced DNMT3a
levels. (C) Protein band intensities from three independent experiments were quantified by densitometry. Changes in the band intensity of
DNMT1, DNMT3a, and SPARC in 5-Aza-CdR–treated samples, relative to untreated controls (set at 100%), are expressed as the mean ±
SEM. DNMT3a, but not DNMT1, was reduced significantly, whereas SPARC was increased significantly in 5-Aza-CdR–treated OVCAR3
(*P < .05) and SKOV3 cell lines (**P < .05) relative to controls. (D) Chromatin immunoprecipitation analysis in SKOV3 cells revealed a
significant DNMT3a association with Sparc promoter, relative to IgG-negative controls (set as 1). RNA polymerase II (RNA Poly) association
was used as a positive control for the assay. (E) Chromatin immunoprecipitation analysis in SKOV3 cells in the absence or presence of
5-Aza-CdR revealed a significant decrease only in DNMT3a levels relative to respective IgG-negative controls (set as 1). Results shown are
representative of two independent experiments performed in triplicates (*P < .05 relative to IgG controls).
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grade. These results confirm an earlier study by Yiu et al. [19]. Scor-
ing of >130 sections of serous ovarian tumor tissues on the tissue
arrays revealed a clear inverse correlation between disease grade and
SPARC protein expression. Furthermore, there was a statistically signifi-
cant decrease in the stromal staining at grade III of the disease. These
results are conclusive, owing to the high number of samples analyzed on
the array. Consistent with the array data were our results on the meth-
ylation of the Sparc promoter in primary tumor tissues. Methylation-
specific PCR results from highly undifferentiated (grade III) LCM
tumor tissues confirmed that Sparc promoter was fully methylated in
a high percentage of samples analyzed. However, owing to the small
number of tumor tissue samples available for analysis, it was not possible
to fully correlate these findings to those of our array results. Further
study is needed to analyze a large number of tumor samples of various
grades to confirm the association between high tumor grade, promoter
methylation, and SPARC expression.
That exogenous SPARC and ectopic SPARC expression through
adenovirus both impair ovarian cancer cell proliferation indicates that
although the cells themselves do not produce SPARC, they retain
responsiveness to SPARC. This supports the hypothesis of an as
yet unidentified endogenous SPARC receptor. Support for this hy-
pothesis can also be found in the previously mentioned studies, all
of which show that neoplasms that do not express SPARC remain
reactive to the protein [19,34,35]. Moreover, a recent report iden-
tified Sparc methylation as a possible biomarker of squamous intra-
epithelial lesions (SILs) and invasive cervical cancer [36]. In that study,
methylation of Sparc observed in liquid Papanicolaou tests occurred
more frequently in high-grade SIL than in low-grade SIL and non-
malignant intraepithelial lesions. These studies, along with our current
data, support the hypothesis that the methylation status of Sparc in
ovarian epithelial cells could potentially be used as a diagnostic tool
as well as a therapeutic treatment of ovarian carcinoma to limit pro-
liferation, induce apoptosis, and prevent metastasis.
In conclusion, we have demonstrated that SPARC expression is sig-
nificantly downregulated in ovarian cancer cells mainly due to the
aberrant methylation of its promoter region by DNMT3a. Further-
more, this down-regulation is necessary for the progression of ovarian
cancer, as ectopic overexpression by adenovirus or addition of exoge-
nous SPARC protein were shown to inhibit the proliferation of ovarian
carcinoma cells. Taken together, these findings highlight a key role for
the methylation of Sparc in the pathogenesis of ovarian cancer.
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Figure W1. Exogenous SPARC inhibits proliferation of normal human
ovarian cells and mesothelial cells. Addition of exogenous SPARC
(10-40 μg/ml) to nonmalignant, immortalized human ovarian cell line
HOSE 1-15 and human mesothelial cell line Meso 301 with high
SPARC expression levels resulted in a significant decrease in the
proliferation rate of the cells as determined by MTS assay. Results
shown are expressed as the mean ± SEM and are representative
of two independent experiments performed in triplicates (*P < .05
vs serum-free media, +P < .05 vs growth media).
